IMMX Latest Press Releases

-- November 12, 2026 --

Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress Globe Newswire 4:15 PM

-- November 4, 2026 --

Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026 Globe Newswire 9:15 AM

-- October 5, 2026 --

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference Globe Newswire 8:45 AM

-- September 30, 2026 --

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock Globe Newswire 5:15 PM

-- September 29, 2026 --

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock Globe Newswire 7:05 AM

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis Globe Newswire 7:00 AM

-- August 11, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX Globe Newswire 6:23 PM

-- August 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX PRNewswire 11:02 PM

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law Business Wire 7:58 PM

-- August 4, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX Globe Newswire 4:49 PM

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Globe Newswire 9:15 AM

-- July 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX PRNewswire 10:01 AM

-- July 20, 2026 --

IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc. Globe Newswire 5:33 PM

IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm Globe Newswire 11:47 AM

Market Data Delayed 15 Minutes